VYNE Therapeutics Inc [NASDAQ: VYNE] loss -72.35% or -1.04 points to close at $0.4 with a heavy trading volume of 37690260 shares.
It opened the trading session at $0.38, the shares rose to $0.4427 and dropped to $0.36, the range by which the price of stock traded the whole day. The daily chart for VYNE points out that the company has recorded -85.26% loss over the past six months.
If we look at the average trading volume of 688.63K shares, VYNE reached to a volume of 37690260 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about VYNE Therapeutics Inc [VYNE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VYNE shares is $4.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VYNE stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for VYNE Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 18, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 06, 2021, representing the official price target for VYNE Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 0.14, with the Price to Cash per share for the same quarter was set at 3.02.
Trading performance analysis for VYNE stock
VYNE Therapeutics Inc [VYNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -72.54. With this latest performance, VYNE shares dropped by -75.87% in over the last four-week period, additionally sinking by -85.26% over the last 6 months – not to mention a drop of -88.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VYNE stock in for the last two-week period is set at 29.09, with the RSI for the last a single of trading hit 0.2693, and the three-weeks RSI is set at 0.2081 for VYNE Therapeutics Inc [VYNE]. The present Moving Average for the last 50 days of trading for this stock 1.1653, while it was recorded at 1.2176 for the last single week of trading, and 2.0509 for the last 200 days.
VYNE Therapeutics Inc [VYNE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and VYNE Therapeutics Inc [VYNE] shares currently have an operating margin of -7513.06%. VYNE Therapeutics Inc’s Net Margin is presently recorded at -6972.73%.
VYNE Therapeutics Inc (VYNE) Capital Structure & Debt Analysis
According to recent financial data for VYNE Therapeutics Inc. ( VYNE), the Return on Equity (ROE) stands at -66.15%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -56.95%, reflecting the company’s efficiency in generating profits from its assets. Additionally, VYNE Therapeutics Inc’s Return on Invested Capital (ROIC) is -95.59%, showcasing its effectiveness in deploying capital for earnings.
VYNE Therapeutics Inc (VYNE) Efficiency & Liquidity Metrics
Based on VYNE Therapeutics Inc’s (VYNE) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
VYNE Therapeutics Inc (VYNE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, VYNE Therapeutics Inc. (VYNE) effectively leverages its workforce, generating an average of -$3245384.62 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.47% and a Quick Ratio of 4.47%, indicating strong ability to cover short-term liabilities.
VYNE Therapeutics Inc [VYNE]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VYNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for VYNE Therapeutics Inc go to -7.18%.
An analysis of Institutional ownership at VYNE Therapeutics Inc [VYNE]
There are presently around $47.70%, or 51.98% of VYNE stock, in the hands of institutional investors. The top three institutional holders of VYNE stocks are: EVENTIDE ASSET MANAGEMENT, LLC with ownership of 1.39 million shares, which is approximately 3.2742%. CORMORANT ASSET MANAGEMENT, LP, holding 1.39 million shares of the stock with an approximate value of $$2.75 million in VYNE stocks shares; and CORMORANT ASSET MANAGEMENT, LP, currently with $$2.39 million in VYNE stock with ownership which is approximately 2.8438%.
